Fractyl Health (NASDAQ:GUTS) Price Target Cut to $10.00 by Analysts at Morgan Stanley

Fractyl Health (NASDAQ:GUTS - Get Free Report) had its price target lowered by equities researchers at Morgan Stanley from $18.00 to $10.00 in a research report issued on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock.

Fractyl Health Trading Down 1.8 %

NASDAQ GUTS traded down $0.03 during trading on Monday, reaching $1.61. 280,087 shares of the stock traded hands, compared to its average volume of 412,245. Fractyl Health has a fifty-two week low of $1.52 and a fifty-two week high of $10.69. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The firm has a market cap of $77.44 million and a price-to-earnings ratio of -0.13. The stock's 50-day moving average price is $2.02 and its 200 day moving average price is $2.47.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. Analysts predict that Fractyl Health will post -1.66 EPS for the current year.

Insider Activity

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $158,566.59. Following the sale, the insider now owns 153,544 shares of the company's stock, valued at $379,253.68. This trade represents a 29.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Harith Rajagopalan sold 90,972 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now owns 491,329 shares in the company, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 274,032 shares of company stock worth $602,979 in the last 90 days.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in shares of Fractyl Health by 166.5% during the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company's stock worth $1,269,000 after purchasing an additional 313,335 shares in the last quarter. BNP Paribas Financial Markets raised its position in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company's stock worth $53,000 after acquiring an additional 7,397 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock valued at $204,000 after acquiring an additional 29,262 shares during the last quarter. Barclays PLC lifted its stake in Fractyl Health by 1,754.7% in the third quarter. Barclays PLC now owns 47,796 shares of the company's stock valued at $121,000 after acquiring an additional 45,219 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Fractyl Health in the 3rd quarter valued at about $33,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.